

REMARKS

Since this application was filed on April 17, 2000, Applicants have refiled this application as a divisional Continued Prosecution Application (CPA) under 37 CFR 1.53(d). Applicants respectfully request reconsideration of the present application in view of the foregoing amendment.

Following entry of this amendment, all pending claims, *i.e.*, claims 17, 21, 25, 30 and 75-77, have been cancelled. Of course, Applicants reserve the right to file one or more continuing applications to the cancelled subject matter. New claims 78-87 have been added. Claims 78-87 are supported by the originally-filed specification and original claims 25-28. Claim 25 was previously withdrawn upon Applicants election of claim 30 (Group IV) in response to the Restriction Requirement of September 4, 2001. Claims 78-87 are directed to methods for identifying an antagonist of MCK-10 ligand binding or MCK-10 activity. These claims do not introduce new matter.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. Nevertheless, the Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Michael M. Smith

By *Reg No. 34,717*

Date *April 21, 2003*

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

for

Beth A. Burrous
Attorney for Applicants
Registration No. 35,087